Alliance Global Partners Upgrades Aptose Biosciences (NASDAQ:APTO) to Strong-Buy

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by research analysts at Alliance Global Partners to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

APTO has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Aptose Biosciences in a report on Wednesday, February 12th. StockNews.com assumed coverage on Aptose Biosciences in a report on Tuesday. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $130.00.

Aptose Biosciences Stock Down 1.8 %

Shares of APTO stock opened at $3.19 on Thursday. The business has a 50-day moving average price of $5.92 and a two-hundred day moving average price of $8.83. Aptose Biosciences has a 12-month low of $3.05 and a 12-month high of $57.00. The firm has a market cap of $6.83 million, a P/E ratio of -1.07 and a beta of 0.88.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.